☆ 3.8 Article

Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model

MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Clinical Neurology

Extended dosing of monoclonal antibodies in multiple sclerosis

Zoe L. E. van Kempen et al.

Summary: Over the past two decades, there has been a significant increase in treatment options for patients with multiple sclerosis (MS). Personalized or extended interval dosing, particularly using monoclonal antibodies, is being increasingly explored as a way to optimize MS therapy. Studies on altered dosing intervals of monoclonal antibodies in MS treatment are ongoing and provide promising insights for future research and clinical practice.

MULTIPLE SCLEROSIS JOURNAL (2022)

添加到收藏夹

Article Economics

Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple Sclerosis

Matthijs M. Versteegh et al.

Summary: This study compared 360 different treatment sequences for patients with relapsing-remitting multiple sclerosis (RRMS) in terms of health outcomes and societal costs. The results showed that the optimal treatment sequence for maximizing health outcomes was not necessarily the most cost-effective option. Treatment decisions should be individually tailored.

VALUE IN HEALTH (2022)

添加到收藏夹

Review Clinical Neurology

Derisking CD20-therapies for long-term use

Ide Smets et al.

Summary: This review proposes six steps to reduce the risks of anti-CD20 therapy, including adequate infectious screening and vaccinations, upfront discussion of family planning, management of infusion reactions, prevention of adverse events, measurement of immunoglobulin levels and review of vaccinations, participation in breast cancer screening programs, and evidence-based dosing and retreatment approaches.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

添加到收藏夹

Article Clinical Neurology

The Economic Burden of Multiple Sclerosis in the United States Estimate of Direct and Indirect Costs

Bruce Bebo et al.

Summary: This study estimates the total economic burden of multiple sclerosis (MS) in the United States in 2019. The findings show that MS has a significant impact on various aspects of patients' lives, including work, physical independence, and social interaction. The study highlights the high cost of prescription drugs and the indirect loss of productivity as important drivers of the economic burden of MS.

NEUROLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial

Anders Svenningsson et al.

Summary: Rifund-MS study provides evidence that rituximab is superior to dimethyl fumarate in preventing relapses in patients with early relapsing-remitting multiple sclerosis. Adverse events such as infusion reactions and gastrointestinal reactions were observed, but there were no safety concerns.

LANCET NEUROLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis

Lawrence Steinman et al.

Summary: Ublituximab shows promise as a treatment for relapsing multiple sclerosis, reducing relapse rates and brain lesions compared to teriflunomide over a 96-week period. However, it does not significantly decrease the risk of disability worsening.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Clinical Neurology

Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis

Imtiaz A. Samjoo et al.

Summary: This study aimed to indirectly compare the efficacy of ofatumumab and ocrelizumab in patients with relapsing multiple sclerosis. While no significant differences were found in disability progression, ofatumumab showed a significant improvement in annualized relapse rate compared to ocrelizumab. Additionally, ofatumumab demonstrated favorable results in terms of no evidence of disease activity and MRI outcomes.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

添加到收藏夹

Article Economics

Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada

Moogeh Baharnoori et al.

Summary: Ofatumumab is cost effective in first-line treatment for RRMS, showing superiority over teriflunomide, interferons, dimethyl fumarate, and ocrelizumab in terms of effectiveness and cost. Compared to glatiramer acetate and best supportive care, Ofatumumab has an incremental cost-effectiveness ratio (ICER) of $24,189/QALY and $28,014/QALY respectively. At a willingness-to-pay threshold of $50,000/QALY, Ofatumumab has a 64.3% probability of being cost effective. In the scenario analysis of second-line therapies, Ofatumumab dominates natalizumab and fingolimod and has an ICER of $50,969 versus cladribine.

PHARMACOECONOMICS-OPEN (2022)

添加到收藏夹

Review Clinical Neurology

Smouldering multiple sclerosis: the 'real MS'

Gavin Giovannoni et al.

Summary: This article challenges the view that multiple sclerosis is purely an inflammatory disease and proposes a more comprehensive pathological process. It also emphasizes the importance of considering systemic disease processes in the management of multiple sclerosis.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2022)

添加到收藏夹

Review Clinical Neurology

Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis

Kelly R. Cotchett et al.

Summary: This article compares the similarities and differences between Rituximab, ocrelizumab, ofatumumab, and ublituximab in the treatment of multiple sclerosis, discussing their efficacy, safety, route of administration, and cost considerations. Ocrelizumab is the only drug approved for primary progressive MS, while infusion/injection related reactions are common adverse events among all four therapies. Ofatumumab stands out for its subcutaneous injection availability, and ublituximab shows promising results in phase II trials for RMS treatment, with phase III trials comparing its efficacy to teriflunomide.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

添加到收藏夹

Review Clinical Neurology

Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis

Amit Bar-Or et al.

Summary: Anti-CD20 therapies have shown significant efficacy in treating multiple sclerosis by depleting B cells and subsets of T cells expressing low levels of CD20. Further understanding of the implications of the different monoclonal antibodies used is crucial for optimizing treatment outcomes.

CNS DRUGS (2021)

添加到收藏夹

Article Economics

Modeling the Cost-Utility of Treatment Sequences for Multiple Sclerosis

Simone Huygens et al.

Summary: A cost-utility model for multiple sclerosis considering treatment switching was developed to provide more realistic estimates of treatment benefits. Short-term treatment switches were predicted accurately, with the escalation DMT sequence showing delayed disease progression. Model results were sensitive to utility values and medical resource consumption.

VALUE IN HEALTH (2021)

添加到收藏夹

Article Clinical Neurology

Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis Data From 2 Different National Strategies

Tim Spelman et al.

Summary: This study investigated the association between national differences in treatment strategies for RRMS and disability outcomes, finding that the Swedish treatment strategy was associated with reduced rates of disability worsening compared to the Danish strategy.

JAMA NEUROLOGY (2021)

添加到收藏夹

Review Clinical Neurology

Rituximab treatment for multiple sclerosis

Benjamin V. Ineichen et al.

MULTIPLE SCLEROSIS JOURNAL (2020)

添加到收藏夹

Article Clinical Neurology

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study

Anna He et al.

LANCET NEUROLOGY (2020)

添加到收藏夹

Article Clinical Neurology

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials

Ludwig Kappos et al.

JAMA NEUROLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Ofatumumab versus Teriflunomide in Multiple Sclerosis

Stephen L. Hauser et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Clinical Neurology

The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis

David Baker et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)

添加到收藏夹

Article Clinical Neurology

Out-of-pocket costs are on the rise for commonly prescribed neurologic medications

Brian C. Callaghan et al.

NEUROLOGY (2019)

添加到收藏夹

Article Clinical Neurology

Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies

Nicky Dunn et al.

MULTIPLE SCLEROSIS JOURNAL (2018)

添加到收藏夹

Article Clinical Neurology

Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies

Nicky Dunn et al.

MULTIPLE SCLEROSIS JOURNAL (2018)

添加到收藏夹

Article Clinical Neurology

Expanded disability status scale progression assessment heterogeneity in multiple sclerosis according to geographical areas

Francesca Bovis et al.

ANNALS OF NEUROLOGY (2018)

添加到收藏夹

Article Clinical Neurology

New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands

Bernard Uitdehaag et al.

MULTIPLE SCLEROSIS JOURNAL (2017)

添加到收藏夹

Article Medicine, General & Internal

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

S. L. Hauser et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Medicine, General & Internal

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

X. Montalban et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Clinical Neurology

New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands

Bernard Uitdehaag et al.

MULTIPLE SCLEROSIS JOURNAL (2017)

添加到收藏夹

Article Clinical Neurology

Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients

Peter Alping et al.

ANNALS OF NEUROLOGY (2016)

添加到收藏夹

Article Clinical Neurology

Rituximab in multiple sclerosis A retrospective observational study on safety and efficacy

Jonatan Salzer et al.

NEUROLOGY (2016)

添加到收藏夹

Article Clinical Neurology

Treatment Effect on Brain Atrophy Correlates with Treatment Effect on Disability in Multiple Sclerosis

Maria Pia Sormani et al.

ANNALS OF NEUROLOGY (2014)

添加到收藏夹

Article Medicine, General & Internal

B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis

Stephen L. Hauser et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.